Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)

Launched by REGINA ELENA CANCER INSTITUTE · Dec 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a dietary supplement containing myo-inositol and selenium on thyroid nodules that are classified as TIR3A, which means they are indeterminate and have a low risk of being cancerous. The researchers want to see if this supplement can help reduce the size and firmness of these nodules over six months. Patients participating in the study will be randomly assigned to either receive the supplement or not, allowing the team to compare the results between the two groups.

To be eligible for this trial, participants must be adults over 18 years old and have a TIR3A thyroid nodule. They should also provide written consent and have samples that can be analyzed for certain markers related to cell growth. However, individuals with diagnosed thyroid cancers, certain hormonal issues, or those who are pregnant or breastfeeding will not be included in the study. If you join the trial, you can expect to have regular check-ups and tests to monitor the nodule's changes throughout the treatment period.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (\>18 years old),
• • both sexes,
• • patients presenting thyroid nodules classified as TIR 3A, based on cytological evaluation on sample from the first fine needle aspiration (FNA),
• • written Informed consent,
• • Patients with appropriate material for subsequent immunocytochemical analysis of Ki-67 and PCNA
• Exclusion Criteria:
• • Patients with diagnosed thyroid malignancies of cytological diagnosis other than TIR3A
• • pathological levels of the thyroid stimulating hormone (TSH) which required L-Thyroxine treatment starting
• • pregnancy and/or breastfeeding